Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 *28/*6 polymorphisms

Japanese Journal of Clinical Oncology

Volumn 41, Issue 4, 2011, Pages 477-482

  Okuyama, Yusuke ^a   Hazama, Shoichi ^b   Nozawa, Hiroshi ^c   Kobayashi, Michiya ^d   Takahashi, Kenichi ^e   Fujikawa, Koshi ^f   Kato, Takeshi ^g   Nagata, Naoki ^h   Kimura, Humihiko ⁱ   Oba, Koji ^j   Sakamoto, Junichi ^k   Mishima, Hideyuki ^l  

^a KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Kouseiren Takaoka Hospital   (Japan)

^d KOCHI MEDICAL SCHOOL   (Japan)

^e AKITA CITY HOSPITAL   (Japan)

^f HOKKAIDO CANCER CENTER   (Japan)

^g Minoh City Hospital   (Japan)

^h Department of Digestive Surgery   (Japan)

ⁱ Itami City Hospital   (Japan)

^j KYOTO UNIVERSITY   (Japan)

^k NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l OSAKA NATIONAL HOSPITAL   (Japan)

more..

Author keywords

FOLFIRI; Irinotecan; Metastatic colorectal cancer; Neutropenia; UGT1A1 polymorphism

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; JAPANESE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JAPAN; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TOPOISOMERASE I INHIBITORS; TREATMENT OUTCOME;

EID: 79953737378     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr001     Document Type: Article

References (20)

1. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989;63:1026-30.
2. de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
3. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-7.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previous untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
7. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
8. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-75.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
10. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
11. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-9.
12. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Gnetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847-54.
13. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
14. Hazama S, Nagashima A, Kondo H, Yoshida S, Shimizu R, Araki A, et al. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci 2010;101:722-7.
15. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
16. Marcuello E, Altes A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678- 82.
17. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A1 genetic polymophisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007;17:497-504.
18. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-5.
19. Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers. Oncology 2009;76:315-21.
20. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.